HR+ breast cancer PDX and PDCL

The Sartorius and Kabos laboratories developed a biobank of transplantable breast cancer patient-derived xenografts (PDX) with an emphasis on HR+ models. Specimens originated from local breast cancer patients and were established and maintained in female NOD/SCID/ILIIrg−/− (NSG) hosts. From these PDX, we generated several patient-derived breast cancer cell lines (PDCL). These were then made resistant to endocrine therapies (estrogen withdrawal (EWD), tamoxifen, and fulvestrant) and sequentially to CDK4/6 inhibition.

Breast Cancer Res Treat. 2012 Sept;135(2):415-32. PMID: 22821401
Cancer Metastasis Rev. 2016 Dec;35(4):547-573. PMID: 28025748
Breast Cancer Res. 2020 Jun 23;22(1):68. PMID: 32576280